Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The Company occupies a 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter brands. The Company is South Africa’s largest supplier of hospital and critical care products. Its footprint extends to India and other territories in sub-Saharan Africa.

The extensive product portfolio includes branded and generic prescription medicines and over-the-counter/fast moving consumer goods (FMCG) brands, intravenous solutions, blood collection products and renal dialysis systems.


To be recognised as a leading world-class branded healthcare company.


The acquisition of NutriLida, a vitamins, minerals and supplements (VMS) company, on 31 July 2011 makes Adcock Ingram the leader in VMS in the FMCG sector.

CEO, Jonathan Louw

Financial highlights

Turnover from continuing operations increased 8% to R4,454 billion
EBITDA from continuing operations decreased 7% to R1,170 billion
HEPS increased 31% to 465,1 cents (2010: 354,8 cents)
Normalised HEPS decreased 9% to 465,1 cents (2010: 509,6 cents)
2,5% ordinary shares bought back

read more



Headline earnings
The Group achieved headline earnings from continuing operations for the year ended 30 September 2011 of R793,9 million (465,1 cents per share). This represents a 28,8% increase over the comparable figure for 2010 of R616,3 million and translates into an increase of 31,1% in headline earnings per share. This result was achieved during a year in which Adcock Ingram was allocated only 4% of the Anti-retroviral (ARV) tender, saw the suspension of sales of dextropropoxyphene-containing (DPP) products and experienced significant upgrade-related production disruptions in its Critical Care facility. It should be noted that the increases calculated for Headline Earnings and HEPS incorporate in the prior year, a R269 million (154,8 cents per share) IFRS 2 charge in relation to the Broad Based Black Economic Empowerment (BBBEE) transaction.

The impact of the acquisitions of NutriLida, Bioswiss, as well as Ayrton Drug Manufacturing Limited (Ayrton) in Ghana, together with the various co-promotion and distribution agreements with multinational (MNC) partners, supported turnover growth of 8% to R4 454 million (2010: R4 130 million). With the significant reduction in DPP and ARV revenue, the decline in revenue excluding acquisitions and MNC revenue was 4.6%.

read more

Financial Statements

arrow Consolidated statements of comprehensive income
arrow Consolidated statement of changes in equity
arrow Consolidated statements of financial position
arrow Consolidated abridged statements of cash flows
arrow Notes to the consolidated financial statements


PDF format Results booklet [PDF - 267MB]
PDF format Presentation [PDF - 2MB]
PDF format PDF downloads
Excel Downloads



Adcock Ingram Abridged Audited Group Results 2011